0001209191-24-000367.txt : 20240103
0001209191-24-000367.hdr.sgml : 20240103
20240103162030
ACCESSION NUMBER: 0001209191-24-000367
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231231
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Borthwick Kathleen
CENTRAL INDEX KEY: 0001987062
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39231
FILM NUMBER: 24506754
MAIL ADDRESS:
STREET 1: C/O PASSAGE BIO, INC.
STREET 2: 2005 MARKET STREET, 39TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Passage BIO, Inc.
CENTRAL INDEX KEY: 0001787297
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 822729751
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE COMMERCE SQUARE
STREET 2: 2005 MARKET STREET, 39TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
BUSINESS PHONE: 2678660312
MAIL ADDRESS:
STREET 1: ONE COMMERCE SQUARE
STREET 2: 2005 MARKET STREET, 39TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-31
0
0001787297
Passage BIO, Inc.
PASG
0001987062
Borthwick Kathleen
ONE COMMERCE SQUARE
2005 MARKET STREET, 39TH FLOOR
PHILADELPHIA
PA
19103
0
1
0
0
SVP, Interim CFO
0
Common Stock
2023-12-31
4
M
0
30000
A
36608
D
Common Stock
2024-01-02
4
S
0
10672
0.91
D
25936
D
Restricted Stock Unit
2023-12-31
4
M
0
30000
0.00
D
Common Stock
30000
0
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Includes 3,082 shares acquired on May 13, 2022 and 3,526 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.
The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
Each RSU represents a contingent right to receive one share of Issuer's common stock.
100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Edgar Cale, Attorney-in-Fact
2024-01-03